Stocktoria
ARROWHEAD PHARMACEUTICALS, INC. ARWR
ARROWHEAD PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $450.8M | $829.4M | $3.6M | $240.7M | $243.2M | $138.3M | $88.0M | $168.8M | $16.1M | $31.4M |
| R&D expense | $739.1M | $607.2M | $505.9M | $353.2M | — | — | — | — | — | — |
| SG&A expense | $202.0M | $123.9M | $98.8M | — | — | — | — | — | — | — |
| Operating income | -$707.2M | $98.3M | -$601.1M | -$205.0M | -$178.5M | -$149.0M | -$93.2M | $61.2M | -$55.9M | -$37.0M |
| Interest expense | — | — | — | $18.3M | $0 | $0 | — | — | — | — |
| Income tax | -$6.8M | $21.4M | -$2.8M | $2.8M | $3.8M | $2,000 | $2,000 | $174,000 | $2,400 | $2,400 |
| Net income | -$724.2M | -$1.6M | -$599.5M | -$205.3M | -$176.1M | -$140.8M | -$84.6M | $68.0M | -$54.5M | -$34.4M |
| EPS (diluted) | $-5.11 | $-0.01 | $-5.00 | $-1.92 | $-1.67 | $-1.36 | $-0.84 | $0.69 | $-0.65 | $-0.47 |
| Operating cash flow | -$271.9M | $179.6M | -$462.9M | -$153.9M | -$136.1M | $171.3M | -$95.8M | $173.0M | -$47.2M | -$23.9M |
| Free cash flow | -$283.9M | $156.9M | -$604.3M | -$330.6M | -$188.9M | $147.7M | -$107.8M | $161.0M | -$48.6M | -$31.9M |
| Cash & equivalents | — | — | — | — | — | $184.4M | $143.6M | $221.8M | $30.1M | $24.8M |
| Inventory | $9.1M | $0 | — | — | — | — | — | — | — | — |
| Total assets | $1.7B | $1.4B | $1.1B | $765.6M | $691.9M | $710.1M | $522.5M | $349.8M | $111.6M | $104.0M |
| Shareholders' equity | $50.5M | $503.4M | $191.1M | $287.2M | $418.3M | $408.8M | $461.8M | $244.6M | $95.8M | $81.4M |
Growth · year-over-year · Revenue CAGR 34.4%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -45.6% | +23258.2% | -98.5% | -1.0% | +75.9% | +57.2% | -47.9% | +945.7% | -48.6% | +19736.5% |
| Net income growth | — | — | — | — | — | — | -224.4% | — | — | — |
| EPS growth | — | — | — | — | — | — | -221.7% | — | — | — |
| Free cash flow growth | -281.0% | — | — | — | -227.9% | — | -166.9% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-09-30. Facts plus Stocktoria's own computed scores — not investment advice.